Pfizer Inc (MIL:1PFE)
€ 24.625 -0.16 (-0.65%) Market Cap: 138.78 Bil Enterprise Value: 192.52 Bil PE Ratio: 34.89 PB Ratio: 1.59 GF Score: 64/100

Celcuity Inc Announces Worldwide Licensing Agreement with Pfizer - Corporate Call Transcript

Apr 08, 2021 / 09:00PM GMT
Operator

Greetings. Welcome to the Celcuity-Pfizer License Agreement Conference. (Operator Instructions)

Please note, this conference is being recorded. I will now turn the conference over to your host, Brian Sullivan, Chief Executive Officer and Co-Founder of Celcuity. Thank you. You may begin.

Brian F. Sullivan
Celcuity Inc. - Co-Founder, Chairman & CEO

Good afternoon, everyone. Thank you for attending this call. We have quite a news to report. We issued 2 press releases today, one announcing a global license agreement with Pfizer for a small molecule inhibitor, gedatolisib; the second press release we issued provides additional details about results from a Phase Ib trial, details about our team and updates on debt financing that we closed today as well.

So turning to Page 2 of the presentation, if you're on the webcast. I'd first start off with the background about the rationale and how we arrived at the decision and ultimately, to license gedatolisib. I'd like to provide an overview of gedatolisib's mechanism and its advantages relative to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot